Validation of HoLISTIC score among adult patients with classical Hodgkin Lymphoma, a single retrospective pilot study at a tertiary medical center

Authors

  • Tawatchai Suwanban Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  • Pravinwan Thungthong Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  • Chajchawan Nakhahes Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  • Kunapa Iam-arunthai Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  • Tananchai Akrawikrai Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
  • Benjamapron Mekrakseree Division of Hematology, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University
  • Supat Chamnanchanunt Faculty of Tropical Medicine, Mahidol University

Keywords:

Hodgkin lymphoma, Prognostic factors, Thailand, HoLISTIC consortium, Cancer

Abstract

Adult Hodgkin lymphoma is a treatable hematologic malignancy. The prognostic factors showed differences between developing and developed countries. Seventy-four  adult patients, with median age of 29.5 years were enrolled. Totally, 32 patients (43.2%) were stage II, 58.1% presented intermediate risk of IPS-3 and 60.8% showed low risk of IPS-7. Reclassified analysis according to IPS-3, -7 and HoLISTIC (HoLS) showed significantly correlated IPS-3 and IPS-7 (P = 0.001), IPS-3 and HoLS score (p <0.001) and IPS-7 and HoLISTIC score (p< 0.001). Patients presenting 2 HoLS scores had a 5-year overall survival (OS) of 71.8% (p = 0.018) and a 5-year progression-free survival (PFS) of 42.1% (p = 0.025). Preexisting B symptoms and anemia were significant lower
for both 5-year OS (p = 0.019, 0.034, respectively) and PFS (p < 0.001, 0.001, respectively). Advanced stage and hypoalbuminemia were significant lower only in 5-year PFS (p < 0.001, = 0.03, respectively). HoLS score might be used among Thai adult patients with Hodgkin lymphoma as other international prognostic factors. 

Downloads

Download data is not yet available.

References

Vellemans H, Andre MPE. Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma. Cancers (Basel). 2021;13:3745.

Momotow J, Borchmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J Clin Med. 2021;10:1125.

Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30:3383-8.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506-14.

Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S. Prognostic factors in hodgkin lymphoma. Mediter J Hematol Infect Dis. 2014;6:e2014053.

Franklin J, Paulus U, Lieberz D, Breuer K, Tesch H, Diehl V. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? Ann Oncol. 2000;11:617-24.

Ganesan P, Dhanushkodi M, Ganesan TS, Radhakrishnan V, Kannan K, Sundersingh S, et al. Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19:116-22.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015;171:530-8.

Rodday AM, Parsons SK, Scharman C, Advani R, Federico M, Friedberg JW ,et al. Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood. 2020;136(Suppl 1):16-8.

Parsons SK, Rodday AM, Scharman C, André M, Federico M , Friedberg JW, et al. The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). J Clin Oncol. 2020;38(15 suppl):e20019.

Ferhanoglu B, Kim TM, Karduss A, Brittain D, Tumyan G, Mansour MA, et al. Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma. Blood. 2020;136:32-4.

Ghafoor T. Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country. Leuk Lymphoma 2020;61:344-50.

Kumar A, Burger IA, Zhang Z, Drill EN, Migliacci JC, Ng A, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica. 2016;101:1237-43. (In eng).

Lopez-Alonso R, Qi S, Mashiach T, Weiler-Sagie M, Yahalom J, Dann EJ. The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT. Leuk Lymphoma. 2021;62:1313-24.

Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. J Clin Oncol. 2023;41:2076-86. (In eng).

Nagpal P, Descalzi-Montoya DB, Lodhi N. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes. Cancer Rep (Hoboken) 2021;4:e1311.

Visser L. Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment? Br J Haematol. 2019;184:119-20.

Downloads

Published

2023-06-22

Issue

Vol. 33 No. 2: April-June 2023

Section

นิพนธ์ต้นฉบับ (Original article)

License

Copyright (c) 2023 Journal of Hematology and Transfusion Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.